182 related articles for article (PubMed ID: 34743547)
21. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
22. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
[TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
Link H; Kerkmann M; Holtmann L; ;
Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
Cinetto F; Neri R; Vianello F; Visentin A; BarilĂ G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.
Abadeh A; Shehadeh S; Betschel S; Waserman S; Cameron DW; Cowan J
PLoS One; 2023; 18(11):e0294408. PubMed ID: 37971974
[TBL] [Abstract][Full Text] [Related]
27. Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.
Shapiro RS; Wasserman RL; Bonagura V; Gupta S
J Clin Immunol; 2017 Feb; 37(2):190-196. PubMed ID: 24477950
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.
Wasserman RL
Allergy Asthma Proc; 2021 Nov; 42(6):489-494. PubMed ID: 34871156
[No Abstract] [Full Text] [Related]
29. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
30. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
Fu LW; Song C; Isaranuwatchai W; Betschel S
Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
[TBL] [Abstract][Full Text] [Related]
31. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
32. Primary Antibody Immunodeficiency and the Pregnant Patient.
Zhang S; Cunningham-Rundles C
Immunol Allergy Clin North Am; 2023 Feb; 43(1):133-144. PubMed ID: 36410999
[TBL] [Abstract][Full Text] [Related]
33. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
Jolles S; Chapel H; Litzman J
Clin Exp Immunol; 2017 Jun; 188(3):333-341. PubMed ID: 28000208
[TBL] [Abstract][Full Text] [Related]
34. Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study.
Pulvirenti F; Cinetto F; Pecoraro A; Carrabba M; Crescenzi L; Neri R; Bonanni L; Fabio G; Agostini C; Spadaro G; Tabolli S; Farrugia A; Quinti I; Milito C
J Clin Immunol; 2019 Feb; 39(2):159-170. PubMed ID: 30644015
[TBL] [Abstract][Full Text] [Related]
35. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
[TBL] [Abstract][Full Text] [Related]
36. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.
Berger M
Immunol Allergy Clin North Am; 2008 May; 28(2):413-37, x. PubMed ID: 18424340
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
Sim B; Ng JY; Teh BW; Talaulikar D
Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
[TBL] [Abstract][Full Text] [Related]
38. Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.
Edgar JDM; Richter AG; Huissoon AP; Kumararatne DS; Baxendale HE; Bethune CA; Garcez T; Misbah SA; Sorensen RU;
J Clin Immunol; 2018 Feb; 38(2):204-213. PubMed ID: 29423883
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
Agostini C; Blau IW; Kimby E; Plesner T
Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
[TBL] [Abstract][Full Text] [Related]
40. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]